VBI snares next-gen VLP tech in Epixis buyout

A French biotech that has earned some global attention for its early-stage work on a hepatitis C vaccine has revealed the name of its mystery buyer. Cambridge, MA-based VBI is acquiring Epixis for an undisclosed sum, touting the potential of its work using next-gen virus-like particles in its treatments. "This acquisition enables VBI to strategically build upon our pipeline of innovative vaccine delivery technologies and advance the development of an extremely promising VLP platform," said VBI President and CEO Jeff Baxter. VBI and Epixis forged a VLP research collaboration focused on cytomegalovirus last year. VBI release

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.